tradingkey.logo
tradingkey.logo
Search

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

ReutersMar 26, 2025 11:42 AM
facebooktwitterlinkedin

- Viking Therapeutics Inc VKTX.O:

  • VIKING THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 TABLET FORMULATION IN PATIENTS WITH OBESITY

  • VIKING THERAPEUTICS INC: EXPECTS TO REPORT DATA FROM STUDY IN SECOND HALF OF 2025.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI